Message Font: Serif | Sans-Serif
 
No. of Recommendations: 2
Not that I want to stop throwing some shade at Sarepta, but I do want to point out that there certainly has been success, at least as an investor, in treating rare diseases. A number of blood cancer treatments started with rare diseases and expanded (say, mantle cell), and and some companies like Alexion and BioMarin were built on conditions I've never heard of.

If you treat less than 5,000 people a year at 300k, you'd top a billion in sales.... Now looking at Novartis' recent gene therapy drug, the price target is, IIRC, between 0.9-1.2 million ... So the gene therapy market is going to be a windfall for whoever can get to right.
Print the post  

Announcements

What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.